| Literature DB >> 31507590 |
Silvia Ricci1, Lorenzo Lodi1, Daniele Serranti2, Marco Moroni3, Gilda Belli3, Giorgia Mancano4, Andrea La Barbera4, Giulia Forzano4, Giusi Mangone1, Giuseppe Indolfi2, Chiara Azzari1.
Abstract
This is the first case of NBAS disease detected by NBS for primary immunodeficiency. NBS with KRECs is revealing unknown potentialities detecting conditions that benefit from early recognition like NBAS deficiency. Immune phenotyping should be mandatory in patients with NBAS deficiency since they can exhibit severe immunodeficiency with hypogammaglobulinemia as the most frequent finding. Fever during infections is a known trigger of acute liver failure in this syndrome, so immune dysfunction, should never go unnoticed in NBAS deficiency in order to start adequate therapy and prophylaxis.Entities:
Keywords: ILFS2; KREC; NBAS; SOPH; immunodeficiency; neuroblastoma amplified sequence deficiency; newborn screening
Mesh:
Substances:
Year: 2019 PMID: 31507590 PMCID: PMC6718460 DOI: 10.3389/fimmu.2019.01955
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Patient's immune phenotyping at different ages.
| Lymphocyte subtypes (cells/mcL) (% of lymphocytes) | 2,813 (16,1%) | 3,112 (18.5%) | 714 (10%) | 1,550 (21%) | 1,835 (20%) | 2,081 (15.1%) | 638 (8.8%) |
| CD19+ | 4 (0%) | 7 (0%) | 3 (0%) | 0 (0%) | 0 (0%) | n.a. | n.a. |
| CD3+ | 2,348 (88%) | 4,428 (95%) | 1,963 (97%) | 1,860 (95%) | 1,575 (95%) | n.a. | n.a. |
| CD3+CD4+ | 2,127 (80%) | 3,714 (79%) | 1,396 (69%) | 1,396 (72%) | 1,370 (83%) | n.a. | n.a. |
| CD3+CD8+ | 189 (7%) | 566 (12%) | 389 (19%) | 401 (21%) | 186 (11%) | n.a. | n.a. |
| CD3−CD16+CD56+ | 261 (10%) | 193 (4%) | 43 (2%) | 72 (4%) | 60 (4%) | n.a. | n.a. |
| CD4+/CD8+ ratio | 11.4 | 6.6 | 3.6 | 3.4 | 7.5 | n.a. | n.a. |
| CD45RA+ | 78% | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. |
| CD45RO+ | 22% | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. |
| CD25+CD127Low | n.a. | 6.7 (n.r. 4–16) | n.a. | n.a. | n.a. | n.a. | n.a. |
| PHA | 85 (n.v. > 80) | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. |
| IL-2 | 83 (n.v. > 80) | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. |
| IgG (mg/dl) | 325 | 213 | n.a. | 182 | 252 | 307 | 539 |
| IgA (mg/dl) | <7.83 | <7.83 | n.a. | <7.83 | <7.83 | <7.83 | 8.2 |
| IgM (mg/dl) | 24 | 34 | n.a. | <52.5 | 35 | 32 | 18 |
| IgE (kU/L) | 108 | 11 | n.a. | n.a. | n.a. | n.a. | n.a. |
n.a., not available; n.v., normal values.
Figure 1Flow cytometric assessment of lymphocyte subsets in healthy control and in our patient (age matched) that show for our patient absence of B cells (CD19+), low CD8+ and NK cells.
Figure 2Representation of 73 patients reported in literature (1, 6, 8–22). 60% of patients (gray area) did not undergo complete immune characterization. 44% of patients who underwent immune characterization presented an immunological impairment (red area).
Figure 3Representation of clinical and laboratory immunological findings (Y-axis) reported among 14 patients (X-axis) who presented a known immunological impairment (including the current case).